Medical device maker AxoGen beats Q3 revenue expectations, hikes FY view
Overview
AxoGen Q3 revenue rises 23.5% yr/yr to $60.1 mln, beating analyst expectations
Adjusted EPS for Q3 beats consensus
Company reports net income of $0.7 mln, reversing a loss from last year
Outlook
Company raises full-year revenue growth guidance to at least 19%, or $222.8 mln
Company expects full-year gross margin between 73% and 75%
FDA approval of Avance Nerve Graft BLA anticipated by December 5, 2025
Result Drivers
BROAD-BASED GROWTH - Revenue growth was broad-based with double-digit increases across all markets, including Extremities, Oral Maxillofacial & Head and Neck, and Breast
EXPANDED COVERAGE - Increased coverage and reimbursement for nerve repair procedures added 1.1 mln covered lives, enhancing market access
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $60.10 mln | $56.80 mln (9 Analysts) |
Q3 Adjusted EPS | Beat | $0.12 | $0.07 (6 Analysts) |
Q3 Adjusted Net Income | $6.10 mln | ||
Q3 Net Income | $700,000 | ||
Q3 Adjusted EBITDA | $9.20 mln | ||
Q3 Gross Margin | 76.60% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for AxoGen Inc is $25.00, about 27.7% above its October 28 closing price of $18.08
The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 32 three months ago
Press Release:
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
